{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:41:56Z","timestamp":1792644116205,"version":"4.5.0"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.ejmech.2026.119332","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T07:01:10Z","timestamp":1790146870000},"page":"119332","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Design and development of novel, potent and brain penetrant cyclic LRRK2 inhibitors for the treatment of Parkinson's disease"],"prefix":"10.1016","volume":"320","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-9710-3417","authenticated-orcid":false,"given":"Wenqing","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianqi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyuan","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangfeng","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Disha","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunlong","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanyu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0363-6608","authenticated-orcid":false,"given":"Ping","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7155-3188","authenticated-orcid":false,"given":"Yunlei","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.ejmech.2026.119332_bib1","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S1474-4422(18)30295-3","article-title":"Global, regional, and national burden of parkinson's disease, 1990\u20132016: a systematic analysis for the global Burden of Disease Study 2016","volume":"17","author":"Dorsey","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejmech.2026.119332_bib2","article-title":"The parkinson Pandemic\u2014A call to action","volume":"75","author":"Dorsey","year":"2017","journal-title":"JAMA Neurol."},{"issue":"9459","key":"10.1016\/j.ejmech.2026.119332_bib3","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0140-6736(05)70801-1","article-title":"Parkinson's disease in China: prevalence in Beijing, Xian, and Shanghai","volume":"365","author":"Zhang","year":"2005","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.ejmech.2026.119332_bib4","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1038\/s41593-019-0423-2","article-title":"Lewy pathology in Parkinson's disease consists of crowded organelles and lipid membranes","volume":"22","author":"Shahmoradian","year":"2019","journal-title":"Nat. Neurosci."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119332_bib5","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41531-022-00367-y","article-title":"Pathophysiological evaluation of the LRRK2 G2385R risk variant for Parkinson's disease","volume":"8","author":"Tezuka","year":"2022","journal-title":"npj Parkinson's Dis."},{"issue":"4","key":"10.1016\/j.ejmech.2026.119332_bib6","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nrneurol.2017.27","article-title":"Cognitive decline in Parkinson disease","volume":"13","author":"Aarsland","year":"2017","journal-title":"Nat. Rev. Neurol."},{"issue":"10","key":"10.1016\/j.ejmech.2026.119332_bib7","first-page":"661","article-title":"Parkinson's disease: clinical review and update, Acta med","volume":"32","author":"Cabreira","year":"2019","journal-title":"Portfolio"},{"issue":"4","key":"10.1016\/j.ejmech.2026.119332_bib8","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1007\/s13311-020-00897-4","article-title":"Autonomic dysfunction in parkinson's disease","volume":"17","author":"Pfeiffer","year":"2020","journal-title":"Neurotherapeutics"},{"issue":"9","key":"10.1016\/j.ejmech.2026.119332_bib9","first-page":"567","article-title":"Caregiver burden in patients with Parkinson's disease, Fortschr","volume":"88","author":"Ransmayr","year":"2020","journal-title":"Neurol. Psychiatr."},{"issue":"3","key":"10.1016\/j.ejmech.2026.119332_bib10","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/mds.25292","article-title":"The current and projected economic burden of Parkinson's disease in the United States","volume":"28","author":"Kowal","year":"2013","journal-title":"Mov. Disord."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119332_bib11","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2165\/00003495-200060010-00007","article-title":"Ropinirole","volume":"60","author":"Matheson","year":"2000","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2026.119332_bib12","series-title":"Parkinson's Disease: Pathogenesis and Clinical Aspects [Internet]","article-title":"Pharmacological treatment of parkinson's disease","author":"Insha Zahoor","year":"2018"},{"issue":"10291","key":"10.1016\/j.ejmech.2026.119332_bib13","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/S0140-6736(21)00218-X","article-title":"Parkinson's disease","volume":"397","author":"Bloem","year":"2021","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ejmech.2026.119332_bib14","first-page":"270","article-title":"Quality of life in Parkinson's disease: a systematic review and meta-analysis of comparative studies, CNS neurosci","volume":"27","author":"Zhao","year":"2021","journal-title":"Ther"},{"issue":"1","key":"10.1016\/j.ejmech.2026.119332_bib15","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s40263-014-0220-0","article-title":"Medication adherence in patients with parkinson's disease","volume":"29","author":"Malek","year":"2015","journal-title":"CNS Drugs"},{"issue":"7","key":"10.1016\/j.ejmech.2026.119332_bib16","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S1474-4422(21)00061-2","article-title":"Progress towards therapies for disease modification in parkinson's disease","volume":"20","author":"Vijiaratnam","year":"2021","journal-title":"Lancet Neurol."},{"issue":"5","key":"10.1016\/j.ejmech.2026.119332_bib17","doi-asserted-by":"crossref","first-page":"899","DOI":"10.3233\/JPD-240272","article-title":"Parkinson's disease drug therapies in the clinical trial pipeline: 2024 update","volume":"14","author":"McFarthing","year":"2024","journal-title":"J. Parkinsons Dis."},{"issue":"5","key":"10.1016\/j.ejmech.2026.119332_bib18","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/mds.27360","article-title":"Disease modification in Parkinson's disease: current approaches, challenges, and future considerations","volume":"33","author":"Lang","year":"2018","journal-title":"Mov. Disord."},{"issue":"2","key":"10.1016\/j.ejmech.2026.119332_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nm.4269","article-title":"\u03b1-synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies","volume":"23","author":"Wong","year":"2017","journal-title":"Nat. Med."},{"issue":"10","key":"10.1016\/j.ejmech.2026.119332_bib20","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1016\/j.celrep.2015.08.001","article-title":"VPS35 deficiency or mutation causes dopaminergic neuronal loss by impairing mitochondrial fusion and function","volume":"12","author":"Tang","year":"2015","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119332_bib21","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s12035-014-8893-4","article-title":"The impact of mitochondrial fusion and fission modulation in sporadic Parkinson's disease","volume":"52","author":"Santos","year":"2015","journal-title":"Mol. Neurobiol."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119332_bib22","first-page":"5","article-title":"Mitochondrial dysfunction and biogenesis in neurodegenerative diseases: pathogenesis and treatment, CNS neurosci","volume":"23","author":"Golpich","year":"2017","journal-title":"Ther"},{"issue":"10","key":"10.1016\/j.ejmech.2026.119332_bib23","first-page":"13193","article-title":"Oxidative stress contributes to abnormal glucose metabolism and insulin sensitivity in two hyperlipidemia models","volume":"8","author":"Bai","year":"2015","journal-title":"Int. J. Clin. Exp. Pathol."},{"issue":"12","key":"10.1016\/j.ejmech.2026.119332_bib24","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/S1474-4422(19)30320-5","article-title":"Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies","volume":"18","author":"Nalls","year":"2019","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119332_bib25","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13024-021-00455-2","article-title":"Identification of sixteen novel candidate genes for late onset Parkinson's disease","volume":"16","author":"Gialluisi","year":"2021","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.ejmech.2026.119332_bib26","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.brainres.2018.06.010","article-title":"LRRK2 and mitochondria: recent advances and current views","volume":"1702","author":"Singh","year":"2019","journal-title":"Brain Res."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119332_bib27","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s10020-021-00281-8","article-title":"Genotype-driven therapeutic developments in Parkinson's disease","volume":"27","author":"Prasuhn","year":"2021","journal-title":"Mol. Med."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119332_bib28","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13024-019-0344-2","article-title":"LRRK2 biology from structure to dysfunction: research progresses, but the themes remain the same","volume":"14","author":"Berwick","year":"2019","journal-title":"Mol. Neurodegener."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119332_bib29","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00441-017-2759-9","article-title":"The LRRK2 signalling system","volume":"373","author":"Price","year":"2018","journal-title":"Cell Tissue Res."},{"key":"10.1016\/j.ejmech.2026.119332_bib30","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.arr.2017.12.007","article-title":"The genetics of Parkinson disease","volume":"42","author":"Deng","year":"2018","journal-title":"Ageing Res. Rev."},{"issue":"4","key":"10.1016\/j.ejmech.2026.119332_bib31","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.neuron.2004.11.005","article-title":"Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology","volume":"44","author":"Zimprich","year":"2004","journal-title":"Neuron"},{"key":"10.1016\/j.ejmech.2026.119332_bib32","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-3-319-49969-7_1","article-title":"Leucine-rich repeat kinase (LRRK2) genetics and Parkinson's Disease","volume":"14","author":"Monfrini","year":"2017","journal-title":"Adv Neurobiol"},{"issue":"2","key":"10.1016\/j.ejmech.2026.119332_bib33","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1042\/BJ20070209","article-title":"LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity","volume":"405","author":"Jaleel","year":"2007","journal-title":"Biochem. J."},{"issue":"5","key":"10.1016\/j.ejmech.2026.119332_bib34","doi-asserted-by":"crossref","DOI":"10.3390\/biom13050845","article-title":"Overview of the impact of pathogenic LRRK2 mutations in parkinson's Disease","volume":"13","author":"Ito","year":"2023","journal-title":"Biomolecules"},{"issue":"451","key":"10.1016\/j.ejmech.2026.119332_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scitranslmed.aar5429","article-title":"LRRK2 activation in idiopathic Parkinson's disease","volume":"10","author":"Di Maio","year":"2018","journal-title":"Sci. Transl. Med."},{"issue":"13","key":"10.1016\/j.ejmech.2026.119332_bib36","doi-asserted-by":"crossref","first-page":"3519","DOI":"10.1016\/j.cell.2021.05.004","article-title":"Structural analysis of the full-length human LRRK2","volume":"184","author":"Myasnikov","year":"2021","journal-title":"Cell"},{"issue":"648","key":"10.1016\/j.ejmech.2026.119332_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scitranslmed.abj2658","article-title":"Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson's disease","volume":"14","author":"Jennings","year":"2022","journal-title":"Sci. Transl. Med."},{"issue":"3","key":"10.1016\/j.ejmech.2026.119332_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/mds.29297","article-title":"LRRK2 inhibition by BIIB122 in healthy participants and patients with Parkinson's disease","volume":"38","author":"Jennings","year":"2023","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ejmech.2026.119332_bib39","unstructured":"https:\/\/investors.denalitherapeutics.com\/news-releases\/news-release-details\/biogen-and-denali-therapeutics-provide-update-phase-2b-luma. ."},{"issue":"8","key":"10.1016\/j.ejmech.2026.119332_bib40","doi-asserted-by":"crossref","first-page":"5377","DOI":"10.1021\/acs.jmedchem.3c00134","article-title":"Macrocycles in drug discovery\u2500learning from the past for the future","volume":"66","author":"Garcia Jimenez","year":"2023","journal-title":"J. Med. Chem."},{"issue":"9","key":"10.1016\/j.ejmech.2026.119332_bib41","doi-asserted-by":"crossref","first-page":"7647","DOI":"10.1021\/acs.jmedchem.4c00520","article-title":"Concurrent optimizations of efficacy and blood\u2013brain barrier permeability in new macrocyclic LRRK2 inhibitors for potential parkinson's disease therapeutics","volume":"67","author":"Kim","year":"2024","journal-title":"J. Med. Chem."},{"issue":"7","key":"10.1016\/j.ejmech.2026.119332_bib42","doi-asserted-by":"crossref","first-page":"8548","DOI":"10.1021\/acs.jmedchem.6c00238","article-title":"Discovery of potent, selective, CNS-penetrant macrocyclic LRRK2 inhibitors for the treatment of parkinson's disease","volume":"69","author":"Yu","year":"2026","journal-title":"J. Med. Chem."},{"issue":"8","key":"10.1016\/j.ejmech.2026.119332_bib43","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1021\/acsmedchemlett.5c00438","article-title":"Novel leucine-rich repeat kinase 2 (LRRK2) inhibitors for the treatment of Parkinson's disease","volume":"16","author":"Song","year":"2025","journal-title":"ACS Med. Chem. Lett."},{"issue":"3","key":"10.1016\/j.ejmech.2026.119332_bib44","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1021\/jm401654j","article-title":"Discovery of highly potent, selective, and brain-penetrant aminopyrazole leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors","volume":"57","author":"Estrada","year":"2014","journal-title":"J. Med. Chem."},{"issue":"6677","key":"10.1016\/j.ejmech.2026.119332_bib45","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1126\/science.adi9926","article-title":"Rab29-dependent asymmetrical activation of leucine-rich repeat kinase 2","volume":"382","author":"Zhu","year":"2023","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.ejmech.2026.119332_bib46","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1021\/jm301297f","article-title":"Demystifying brain penetration in central nervous system drug discovery","volume":"56","author":"Di","year":"2013","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119332_bib47","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1021\/cn200100h","article-title":"Knowledge-based, Central Nervous system (CNS) lead selection and lead optimization for CNS drug discovery","volume":"3","author":"Ghose","year":"2012","journal-title":"ACS Chem. Neurosci."},{"issue":"3","key":"10.1016\/j.ejmech.2026.119332_bib48","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.tibs.2012.11.006","article-title":"What makes a P450 tick?","volume":"38","author":"Munro","year":"2013","journal-title":"Trends Biochem. Sci."},{"issue":"11","key":"10.1016\/j.ejmech.2026.119332_bib49","doi-asserted-by":"crossref","first-page":"3808","DOI":"10.1021\/jm0489713","article-title":"Predictive three-dimensional quantitative structure\u2212activity relationship of cytochrome P450 1A2 inhibitors","volume":"48","author":"Korhonen","year":"2005","journal-title":"J. Med. Chem."},{"issue":"19","key":"10.1016\/j.ejmech.2026.119332_bib50","doi-asserted-by":"crossref","first-page":"14348","DOI":"10.1074\/jbc.M611692200","article-title":"Adaptations for the oxidation of polycyclic aromatic hydrocarbons exhibited by the structure of human P450 1A2","volume":"282","author":"Sansen","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2026.119332_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccr.2020.213600","article-title":"Molecular probes for human cytochrome P450 enzymes: recent progress and future perspectives","volume":"427","author":"Wu","year":"2021","journal-title":"Coord. Chem. Rev."},{"issue":"7","key":"10.1016\/j.ejmech.2026.119332_bib52","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1021\/acs.jmedchem.7b00045","article-title":"Discovery of a 3-(4-Pyrimidinyl) indazole (MLi-2), an orally available and selective leucine-rich repeat kinase 2 (LRRK2) inhibitor that reduces brain kinase activity","volume":"60","author":"Scott","year":"2017","journal-title":"J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426007774?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426007774?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:25:40Z","timestamp":1792643140000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426007774"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":52,"alternative-id":["S0223523426007774"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119332","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design and development of novel, potent and brain penetrant cyclic LRRK2 inhibitors for the treatment of Parkinson's disease","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119332","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119332"}}